Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Collegium Pharmaceutical Inc (COLL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: COLL (1-star) is a SELL. SELL since 1 days. Simulated Profits (21.40%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $44.6
1 Year Target Price $44.6
| 2 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 40.55% | Avg. Invested days 48 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.10B USD | Price to earnings Ratio 32.94 | 1Y Target Price 44.6 |
Price to earnings Ratio 32.94 | 1Y Target Price 44.6 | ||
Volume (30-day avg) 5 | Beta 0.63 | 52 Weeks Range 23.23 - 42.29 | Updated Date 09/16/2025 |
52 Weeks Range 23.23 - 42.29 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 5.13% | Operating Margin (TTM) 20.02% |
Management Effectiveness
Return on Assets (TTM) 7.76% | Return on Equity (TTM) 16.16% |
Valuation
Trailing PE 32.94 | Forward PE 5.21 | Enterprise Value 1782616379 | Price to Sales(TTM) 1.56 |
Enterprise Value 1782616379 | Price to Sales(TTM) 1.56 | ||
Enterprise Value to Revenue 2.52 | Enterprise Value to EBITDA 5.14 | Shares Outstanding 31502100 | Shares Floating 28098322 |
Shares Outstanding 31502100 | Shares Floating 28098322 | ||
Percent Insiders 1.72 | Percent Institutions 116.63 |
Upturn AI SWOT
Collegium Pharmaceutical Inc
Company Overview
History and Background
Collegium Pharmaceutical, Inc., founded in 2002, focuses on developing and commercializing pain management products with abuse-deterrent properties. Initially focused on REMS programs, it evolved into a company focused on responsible opioid prescribing.
Core Business Areas
- Pain Management: Develops and commercializes products designed to treat pain, primarily focusing on abuse-deterrent formulations of opioids and non-opioid pain treatments.
- Commercialization: Markets and sells its products directly to healthcare providers and patients through its commercial infrastructure.
Leadership and Structure
Collegium Pharmaceutical Inc's leadership team includes a CEO, CFO, CMO and a board of directors. The organizational structure is typical of a publicly traded pharmaceutical company with functional departments such as research and development, commercial operations, finance, and legal.
Top Products and Market Share
Key Offerings
- Xtampza ER: Xtampza ER is an extended-release oxycodone formulation designed with abuse-deterrent properties. It's a major revenue driver for Collegium. Market share data specifics are difficult to find and vary, but it competes with other extended-release opioids. Competitors include Purdue Pharma (OxyContin) and other generic opioid manufacturers.
- Nucynta ER: Nucynta ER (tapentadol extended-release) provides a non-opioid option for pain relief. Collegium competes with other companies offering non-opioid pain relievers like Tylenol and Advil (OTC) and other prescription analgesics. Market share data for Nucynta ER will require a search but is available to the industry, but not general public.
Market Dynamics
Industry Overview
The pharmaceutical industry is heavily regulated, research-intensive, and driven by innovation. The pain management sector faces scrutiny due to the opioid crisis, leading to a focus on abuse-deterrent formulations and non-opioid alternatives.
Positioning
Collegium Pharmaceutical Inc positions itself as a leader in responsible pain management by offering abuse-deterrent opioid formulations and non-opioid treatment. This differentiates them in a market increasingly concerned with opioid misuse.
Total Addressable Market (TAM)
The TAM for pain management is substantial, estimated in the tens of billions of dollars globally. Collegium Pharmaceutical Inc's market position is focused on gaining share in the extended-release opioid and non-opioid space.
Upturn SWOT Analysis
Strengths
- Abuse-deterrent technology
- Focus on responsible pain management
- Established commercial infrastructure
- Strong IP protection on key products
Weaknesses
- Reliance on a limited number of products
- Exposure to opioid litigation risks
- Competition from generic opioids
- Dependency on product patent protection
Opportunities
- Expansion into new pain management markets
- Development of novel non-opioid analgesics
- Partnerships for distribution and co-development
- Acquisition of complementary pain management assets
Threats
- Increased regulatory scrutiny of opioids
- Generic competition eroding market share
- Opioid-related litigation and liabilities
- Changing prescribing patterns due to opioid crisis
Competitors and Market Share
Key Competitors
- PRGO
- TEVA
- VTRS
Competitive Landscape
Collegium Pharmaceutical Inc faces intense competition from both branded and generic pharmaceutical companies in the pain management market. Its competitive advantages lie in its abuse-deterrent technology and focus on responsible pain management. Disadvantages include its smaller size and limited product portfolio compared to larger competitors.
Major Acquisitions
Assertio Therapeutics, Inc.
- Year: 2022
- Acquisition Price (USD millions): 580
- Strategic Rationale: The acquisition of Assertio Therapeutics expanded Collegium Pharmaceutical Inc's product portfolio and strengthened its commercial presence in the pain management market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth can be assessed by reviewing past annual reports and financial statements to ascertain sales and revenue of pain product(s).
Future Projections: Future projections are available from analyst estimates which can be found on financial news resources.
Recent Initiatives: Recent initiatives may include product launches, acquisitions, research and development programs.
Summary
Collegium Pharmaceutical Inc is a pharmaceutical company focused on responsible pain management through abuse-deterrent opioids and non-opioid treatments. The company's strength lies in its differentiated technology and focus on responsible practices, though it faces risks associated with the opioid crisis and generic competition. Collegium needs to carefully manage its opioid-related liabilities while seeking growth through new product development and strategic acquisitions. Its recent acquisition improved its scale, however it also needs to manage integration well. Competitors will erode market share if they are not proactive on innovation or through new product acquisitions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Financial News Outlets
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice. Investment decisions should be based on individual due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Collegium Pharmaceutical Inc
Exchange NASDAQ | Headquaters Stoughton, MA, United States | ||
IPO Launch date 2015-05-07 | CEO, President, Executive VP & Director Mr. Vikram Karnani | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 357 | Website https://www.collegiumpharma.com |
Full time employees 357 | Website https://www.collegiumpharma.com | ||
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.